Veracyte/VCYT

$23.67

0.47%
-
1D1W1MYTD1YMAX

About Veracyte

Veracyte, Inc. is a global diagnostics company. The Company is engaged in the development and commercialization of diagnostic products and biopharmaceutical services. It offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. It also offers an Immunogram, which provides an understanding of the tumor immune microenvironment by integrating data from a variety of genomic, transcriptomic, and proteomic platforms. Its tests in the United States are serviced through its own CLIA-certified laboratories in South San Francisco and San Diego, California and Austin, Texas. It also offers customized biomarker testing and analytical services.

Ticker

VCYT

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Marc Stapley

Employees

787

Headquarters

South san francisco, United States

Veracyte Metrics

BasicAdvanced
$1.68B
Market cap
-
P/E ratio
-$1.02
EPS
1.62
Beta
-
Dividend rate

What the Analysts think about Veracyte

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
33.8% upside
High $37.00
Low $21.00
$23.67
Current price
$31.67
Average price target

Veracyte Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-28.74% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$98.1M
8.88%
Net income
$-28.2M
-4.73%
Profit margin
-28.74%
-12.51%

Veracyte Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 179.62%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.11
-$0.12
-$0.41
-
Expected
-$0.13
-$0.15
-$0.15
-$0.13
Surprise
-17.76%
-21.44%
179.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Veracyte stock

Buy or sell Veracyte stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing